Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Ferraresso Michael

2. Date of Event Requiring Statement (MM/DD/YYYY) 3/10/2021

3. Issuer Name and Ticker or Trading Symbol

AVEO PHARMACEUTICALS, INC. [AVEO]

(Last) (First) (Middle)

C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Commercial Officer /

(Street)

BOSTON, MA 02108

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3284	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	12/4/2027	Common Stock	20000	$28.30	D
Stock Option (right to buy)	⁽²⁾	2/1/2028	Common Stock	3740	$30.80	D
Stock Option (right to buy)	⁽³⁾	2/6/2029	Common Stock	35064	$6.20	D
Stock Option (right to buy)	⁽⁴⁾	2/5/2030	Common Stock	42499	$5.60	D
Stock Option (right to buy)	⁽⁵⁾	2/5/2031	Common Stock	100000	$9.12	D

Explanation of Responses:
(1)	25% of the shares underlying this option vested on December 4, 2018, and the remainder of this option vest in equal monthly installments from December 4, 2018, through December 4, 2021 subject to the Reporting Person's continued service to the Company.
(2)	The shares underlying this option vest in equal monthly installments from February 1, 2018, through February 1, 2022, subject to the Reporting Person's continued service to the Company.
(3)	The shares underlying this option vest in equal monthly installments from February 6, 2019 through February 6, 2023, subject to the Reporting Person's continued service to the Company.
(4)	The shares underlying this option vest in equal monthly installments from February 5, 2020 through February 5, 2024, subject to the Reporting Person's continued service to the Company.
(5)	The shares underlying this option vest in equal monthly installments from February 5, 2021, through February 5, 2025, subject to the Reporting Person's continued service to the Company.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Ferraresso Michael C/O AVEO PHARMACEUTICALS, INC. 30 WINTER STREET BOSTON, MA 02108			Chief Commercial Officer